Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
Since 2019, systemic treatments for metastatic kidney cancer have shifted from drugs targeting selected proteins to immunotherapy. Our results show trends over time for more favorable characteristics among patients receiving systemic treatment and improvements in survival.
Authors
- Adriaan D. Bins
- Katja K.H. Aben (ORCID: https://orcid.org/0000-0002-0214-2147)
- Martijn G.H. van Oijen (ORCID: https://orcid.org/0000-0003-4581-1440)
- Hilin Yildirim (ORCID: https://orcid.org/0000-0003-0965-7968)
- Anke Richters (ORCID: https://orcid.org/0000-0002-1580-1543)
- Arnoud W. Postema (ORCID: https://orcid.org/0000-0003-0629-871X)
- Maureen J.B. Aarts (ORCID: https://orcid.org/0000-0002-6381-1500)
- Patricia Zondervan (ORCID: https://orcid.org/0000-0003-0812-078X)
Institutions
- Radboud University Nijmegen (NL)
- Leiden University Medical Center (NL)
- Maastricht University Medical Centre (NL)
- Radboud University Medical Center (NL)
- Netherlands Comprehensive Cancer Organisation (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- European Urology Open Science
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1016/j.euros.2025.01.008
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00